Key result
Serum neuregulin-1β levels fail to differentiate ACS or MI in emergency department presentations.
Why the study?
Does a single serum neuregulin-1β measurement at emergency department presentation accurately diagnose myocardial infarction or acute coronary syndrome in patients with symptoms suggestive of acute ischemia?
Cohort (n=319)
No
Does a single serum neuregulin-1β measurement at emergency department presentation accurately diagnose myocardial infarction or acute coronary syndrome in patients with symptoms suggestive of acute ischemia?
A single serum neuregulin-1β measurement at emergency department presentation has no diagnostic utility (AUC ~0.50) for identifying acute myocardial infarction or acute coronary syndrome.
Answers are grounded in this paper and cite their sources.
Neuregulin-1β lacks diagnostic utility for ACS or MI at ED presentation; leaves open value in other contexts or with serial testing.
The purpose of this study was to determine the diagnostic test characteristics of serum neuregulin-1β (NRG-1β) for the detection of acute coronary syndrome (ACS). We recruited emergency department patients presenting with signs and symptoms prompting an evaluation for ACS. Serum troponin and neuregulin-1β levels were compared between those who had a final discharge diagnosis of myocardial infarction (STEMI and NSTEMI) and those who did not, as well as those who more broadly had a final discharge diagnosis of ACS (STEMI, NSTEMI, and unstable angina). Of 319 study participants, 11% had evidence of myocardial infarction, and 19.7% had a final diagnosis of ACS. Patients with MI had median neuregulin levels of 0.16 ng/mL (IQR [0.16-24.54]). Compared to the median of those without MI, 1.46 ng/mL (IQR [0.16-15.02]), there was no significant difference in the distribution of results (P = 0.63). Median neuregulin levels for patients with ACS were 0.65 ng/mL (IQR [0.16-24.54]). There was no statistical significance compared to those without ACS who had a median of 1.40 ng/mL (IQR [0.16-14.19]) (P = 0.95). Neuregulin did not perform successfully as a biomarker for acute MI or ACS in the emergency department.
No takes yet. Share an insight, caveat, or question.
Yiadom et al. (2016) conducted a cohort in Suspected acute coronary syndrome (ACS) (n=319). Serum neuregulin-1β (NRG-1β) measurement vs. Patients without ACS or without myocardial infarction was evaluated on Final discharge diagnosis of acute coronary syndrome (STEMI, NSTEMI, or unstable angina) (OR 1.01, p=0.95). Serum neuregulin-1β levels at ED presentation did not differ between patients with and without ACS or MI.
Synapse has enriched 10 related papers. Consider them for comparative context: